In biopharmaceutical production, proteins are expressed from genetically engineered host cell systems. Despite the downstream purification steps used to remove cellular components and host cell proteins (HCPs) some HCPs can remain. The residual presence of HCPs in a biopharmaceutical product may lead to serious immunogenic response in humans or can lead to degradation of the drug product. In this webinar, we will discuss how moving to LC-MS from tools like ELISA can improve host cell protein identification and monitoring. We will discuss how an LC-MS instrument platform delivers superior detection and determination of HCPs compared to other instruments on the market. Helping you to ensure patient safety through development.
These webinars are delivered live with interactive Q&A sessions designed to connect you directly with leading scientists on current advances. Join us to jump-start the upgrade of methodologies in your lab with cutting edge analytical capabilities and applications.
Key Learning Objectives:
Who Should Attend: